Skip to content

OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) reimbursed for treatment of unresectable malignant mesothelioma

Microscopic view of Mesothelioma cancer cells infiltrating the beige fibrous lung pleura.
This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:

Articles you might be interested in

Scroll To Top